HWM
TEVA icon

HighMark Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

HighMark Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-400
Closed -$3K – 566
2022
Q3 		$3K Hold
400
– – ﹤0.01% 405
2022
Q2 		$3K Hold
400
– – ﹤0.01% 412
2022
Q1 		$4K Hold
400
– – ﹤0.01% 397
2021
Q4 		$3K Sell
400
-1,682
-81% -$15.2K ﹤0.01% 419
2021
Q3 		$20K Buy
2,082
+84
+4% +$787 0.01% 182
2021
Q2 		$20K Sell
1,998
-672
-25% -$7.11K 0.01% 188
2021
Q1 		$31K Sell
2,670
-644
-19% -$7.38K 0.02% 138
2020
Q4 		$32K Sell
3,314
-6,093
-65% -$58.4K 0.03% 129
2020
Q3 		$85K Buy
9,407
+7,252
+337% +$76.7K 0.08% 72
2020
Q2 		$27K Buy
2,155
+846
+65% +$9.57K 0.03% 114
2020
Q1 		$11K Hold
1,309
– – 0.01% 147
2019
Q4 		$12K Buy
+1,309
New +$11.7K 0.01% 182

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

HighMark Wealth Management's TEVA Position: Q4 2022 in Review

HighMark Wealth Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2022, closing a stake of 400 shares — an estimated $3K sold.

HighMark Wealth Management first reported a position in TEVA in Q4 2019 and held it in 12 quarters. The position peaked at $85K in Q3 2020. 422 funds tracked by Wall St. Rank hold TEVA as of Q4 2022.

  • HighMark Wealth Management reported no remaining Teva Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • HighMark Wealth Management sold 400 Teva Pharmaceuticals shares in Q4 2022, an estimated $3K.
  • HighMark Wealth Management first reported a position in Teva Pharmaceuticals in Q4 2019 and held it in 12 quarters.
  • HighMark Wealth Management's Teva Pharmaceuticals position peaked at $85K in Q3 2020.
  • 422 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2022.

Based on HighMark Wealth Management's 13F filing for Q4 2022, filed 2 Feb 2023.